// App-Quantinova.ai

OP0053 : SECUKINUMAB IMPROVES CLINICAL AND IMAGING OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS WITH INADEQUATE RESPONSE TO NSAIDS: WEEK 52 RESULTS FROM THE MAXIMISE TRIAL

Researchers

Presenter

  • X. Baraliakos

Principal Investigators

  • L. Gossec

  • E. Pournara

  • S. Jeka

  • R. Blanco

  • S. Dangelo

  • G. Schett

  • B. Schulz

  • M. Rissler

  • K. Nagar

  • C. Perella

  • L. C. Coates

Medical Centers

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Sorbonne Universites, Paris, France

  • Novartis AG, Basel, Switzerland

  • University Hospital No. , Bydgoszcz, Poland

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • University of Oxford, Oxford, United Kingdom

Locations

  • Germany

  • France

  • Switzerland

  • Poland

  • Spain

  • Italy

  • India

  • United Kingdom

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02721966

Sponsors

  • Novartis Pharma

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved